IMUNON to Participate in Upcoming Investor Conferences
IMUNON (Nasdaq: IMNN) announced that President and Chief Executive Officer Stacy Lindborg will participate in two investor conferences in October 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
IMUNON (Nasdaq: IMNN) announced that President and Chief Executive Officer Stacy Lindborg will participate in two investor conferences in October 2026. At the Maxim Growth Summit, held October 12–14 at the Hard Rock Hotel in New York, she will join an oncology panel on October 14 at 9:00 a.m. ET.
At the ThinkEquity Conference on October 15 at the Mandarin Oriental Hotel in New York, her presentation is scheduled for 1:30 p.m. ET in the Boardroom. IMUNON will also host one-on-one meetings throughout the conferences.
Details
Market Reaction – IMNN
On Oct 8, the day this news came out, the latest delayed price for IMNN is 4.82% below the previous close. Our momentum scanner has recorded 5 alerts for this stock so far that day. The latest delayed price is $1.08.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LAWRENCEVILLE, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that Stacy Lindborg, Ph.D., President and Chief Executive Officer, will participate in the following October 2026 investor conferences.
Maxim Growth Summit 2026
Date: October 12 - 14, 2026
Location: Hard Rock Hotel, New York, NY
Presentation: Oncology Panel, October 14, 2026, at 9:00 a.m. ET
For more information and a complete agenda of the Maxim Growth Summit, please visit https://www.maximgrp.com/2026-growth-summit.
2026 ThinkEquity Conference
Date: October 15, 2026
Location: Mandarin Oriental Hotel, New York, NY
Presentation: 1:30 p.m. ET in the Boardroom
For more information and a complete agenda of the ThinkEquity Conference, please visit https://www.think-equity.com/thinkequity-conference.
The Company will host 1x1 meetings throughout the conferences. For more information or to schedule a meeting, please contact Maxim Group or ThinkEquity conference representatives or email imunon@kcsa.com.
About IMUNON
IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA-based gene therapy technology across its modalities. The first modality, TheraPlas®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response.
The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy being developed for the localized treatment of advanced ovarian cancer. IMNN-001 has been evaluated in multiple clinical trials including one Phase 2 clinical trial (OVATION 2) and is currently being studied in the ongoing Phase 3 clinical trial (OVATION 3). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit www.imunon.com.
Investor Contact:
Valter Pinto
KCSA Strategic Communications
212-896-1254
imunon@kcsa.com
